Gilead’s Q2 2025 Highlights

Gilead reported Q2 2025 earnings last week, announcing total revenue of approximately $7.1 billion and non-GAAP EPS of $2.01. It raised full-year product sales guidance to $28.3-28.7 billion, driven by continued strength in its core HIV franchise and double-digit growth from its oncology drug Trodelvy.

August 15, 2025

US Biotech IPOs: H1 2025 Performance Update

Only eight biotech companies have gone public thus far in 2025, marking a multi-year low. Investor enthusiasm remains cautious amid uncertainty surrounding FDA regulation and drug pricing policy, contributing to a roughly 4.5% YTD decline in the XBI. Despite these challenges, certain stocks have significantly outperformed the broader sector.

August 06, 2025

J&J’s Q2 2025 Highlights: Innovative Medicine Drives Growth Despite Stelara Slowdown

J&J’s blockbuster drug Stelara saw sales plunge 43% in Q2 2025, yet the company still delivered a solid overall performance driven by its Innovative Medicines segment, which crossed $15 billion in quarterly sales for the first time.

July 31, 2025

Merck’s $10B Verona Acquisition: Ohtuvayre Leads Next-Gen COPD Innovation

Merck & Co. announced that it will acquire U.K.-based Verona Pharma for $10 billion. This comes shortly after the FDA approved Ohtuvayre in June 2024, the first novel inhaled COPD maintenance medication in over twenty years.

July 21, 2025

Who will transform the HAE Market?

Hereditary angioedema (HAE)—a niche rare disease market worth billions—is becoming an innovation hotspot. Ionis and KalVista promise transformative solutions. What are the pros and cons of each?

April 06, 2025